Evidence map›Paper›PMID 38290895›Full record

ReviewBlood reviews2024

Harnessing multi-source data for individualized care in Hodgkin Lymphoma.

Susan K Parsons, Angie Mae Rodday, Jenica N Upshaw, Carlton D Scharman, Zhu Cui, Yenong Cao, Yun Kyoung Ryu Tiger, Matthew J Maurer, Andrew M Evens

Abstract readReview
In one paragraph

Review in Blood reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Hodgkin lymphoma: great progress with room for improvement.Nature reviews. Clinical oncology · 2025
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Susan K ParsonsInstitute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, United States of America; Division of Hematology/Oncology, Tufts Medical Center, Boston, MA, United States of America. Electronic address: sparsons@tuftsmedicalcenter.org.
Angie Mae RoddayInstitute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, United States of America.
Jenica N UpshawInstitute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, United States of America; The CardioVascular Center and Advanced Heart Failure Program, Tufts Medical Center, Boston, MA, United States of America.
Carlton D ScharmanUCSF-Washington Center, Fremont, CA, United States of America.
Zhu CuiInstitute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, United States of America; Division of Hematology/Oncology, Tufts Medical Center, Boston, MA, United States of America.
Yenong CaoInstitute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, United States of America; Division of Hematology/Oncology, Tufts Medical Center, Boston, MA, United States of America.
Yun Kyoung Ryu TigerDivision of Blood Disorders, Rutgers Cancer Institute New Jersey, New Brunswick, NJ, United States of America.
Matthew J MaurerDivision of Clinical Trials and Biostatistics and Division of Hematology, Mayo Clinic, Rochester, MN, United States of America.
Andrew M EvensDivision of Blood Disorders, Rutgers Cancer Institute New Jersey, New Brunswick, NJ, United States of America.

Funding

Modeling Multi-Source Data in Hodgkin LymphomaR01CA262265 · NCI · TUFTS MEDICAL CENTER · PI Andrew M Evens, Susan Kenyon Parsons · 2022 to 2026
$3.6M
Prevention of Anthracycline Chemotherapy CardiotoxicityK08HL146959 · NHLBI · TUFTS MEDICAL CENTER · PI UPSHAW, JENICA · 2020 to 2024
$885k
NCI NIH HHS R01 CA262265NHLBI NIH HHS K08 HL146959
6 · The paper itself

Abstract

Hodgkin lymphoma is a rare, but highly curative form of cancer, primarily afflicting adolescents and young adults. Despite multiple seminal trials over the past twenty years, there is no single consensus-based treatment approach beyond use of multi-agency chemotherapy with curative intent. The use of radiation continues to be debated in early-stage disease, as part of combined modality treatment, as well as in salvage, as an important form of consolidation. While short-term disease outcomes have varied little across these different approaches across both early and advanced stage disease, the potential risk of severe, longer-term risk has varied considerably. Over the past decade novel therapeutics have been employed in the retrieval setting in preparation to and as consolidation after autologous stem cell transplant. More recently, these novel therapeutics have moved to the frontline setting, initially compared to standard-of-care treatment and later in a direct head-to-head comparison combined with multi-agent chemotherapy. In 2018, we established the HoLISTIC Consortium, bringing together disease and methods experts to develop clinical decision models based on individual patient data to guide providers, patients, and caregivers in decision-making. In this review, we detail the steps we followed to create the master database of individual patient data from patients treated over the past 20 years, using principles of data science. We then describe different methodological approaches we are taking to clinical decision making, beginning with clinical prediction tools at the time of diagnosis, to multi-state models, incorporating treatments and their response. Finally, we describe how simulation modeling can be used to estimate risks of late effects, based on cumulative exposure from frontline and salvage treatment. The resultant database and tools employed are dynamic with the expectation that they will be updated as better and more complete information becomes available.

Indexed as

Hodgkin DiseaseAdolescentAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyDisease ProgressionHumansNeoplasm Recurrence, LocalStem Cell TransplantationYoung AdultHodgkin lymphomaMulti-state modelingOutcomesPrediction modeling

Identifiers

PMID38290895
PMCPMC11382606

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.